SG10201901189SA - Substituted piperidine compounds - Google Patents

Substituted piperidine compounds

Info

Publication number
SG10201901189SA
SG10201901189SA SG10201901189SA SG10201901189SA SG10201901189SA SG 10201901189S A SG10201901189S A SG 10201901189SA SG 10201901189S A SG10201901189S A SG 10201901189SA SG 10201901189S A SG10201901189S A SG 10201901189SA SG 10201901189S A SG10201901189S A SG 10201901189SA
Authority
SG
Singapore
Prior art keywords
compounds
present disclosure
substituted piperidine
piperidine compounds
formula
Prior art date
Application number
SG10201901189SA
Inventor
Lorna Helen Mitchell
Andrew Simon Bell
Richard Chesworth
Megan Alene Cloonan Foley
Kevin Wayne Kuntz
James Edward John Mills
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of SG10201901189SA publication Critical patent/SG10201901189SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SUBSTITUTED PIPERIDI NE COMPOUNDS The present disclosure provides substituted piperidine compounds having Formula I: I and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. [No Figure]
SG10201901189SA 2014-09-10 2015-09-09 Substituted piperidine compounds SG10201901189SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048771P 2014-09-10 2014-09-10
US201462078845P 2014-11-12 2014-11-12
US201562146790P 2015-04-13 2015-04-13

Publications (1)

Publication Number Publication Date
SG10201901189SA true SG10201901189SA (en) 2019-03-28

Family

ID=55459535

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201901189SA SG10201901189SA (en) 2014-09-10 2015-09-09 Substituted piperidine compounds
SG11201701597RA SG11201701597RA (en) 2014-09-10 2015-09-09 Substituted piperidine compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701597RA SG11201701597RA (en) 2014-09-10 2015-09-09 Substituted piperidine compounds

Country Status (13)

Country Link
US (1) US10577363B2 (en)
EP (1) EP3193605A4 (en)
JP (1) JP2017528464A (en)
KR (1) KR20170047397A (en)
CN (1) CN107072207A (en)
AU (1) AU2015315182A1 (en)
BR (1) BR112017004589A2 (en)
CA (1) CA2960280A1 (en)
EA (1) EA201790327A1 (en)
IL (1) IL250888A0 (en)
MX (1) MX2017002986A (en)
SG (2) SG10201901189SA (en)
WO (1) WO2016040515A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
US10266526B2 (en) 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
CA2960279A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
AU2015315167A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamide compounds
WO2016136963A1 (en) 2015-02-27 2016-09-01 彰彦 石川 Method for producing kakeromycin and derivatives thereof
US10752620B2 (en) * 2016-07-28 2020-08-25 Idorsia Pharmaceuticals Ltd. Piperdine CXCR7 receptor modulators
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
TWI822724B (en) 2018-01-26 2023-11-21 瑞士商愛杜西亞製藥有限公司 Crystalline forms of (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
JPWO2021065898A1 (en) 2019-09-30 2021-04-08
CN114702552B (en) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 MTORC2 inhibitors
CN117800895A (en) * 2022-09-30 2024-04-02 苏州阿尔脉生物科技有限公司 Oxalic acid amine derivative, pharmaceutical composition containing oxalic acid amine derivative and medical application of oxalic acid amine derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228288B (en) * 1989-01-09 1991-06-07 Zambon Spa COMPOUNDS WITH ANTI-SEROTONIN ACTIVITY
SE9902987D0 (en) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE0403106D0 (en) 2004-12-20 2004-12-20 Astrazeneca Ab Chemical compounds
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
TW200930713A (en) * 2007-12-03 2009-07-16 Takeda Pharmaceutical Nitrogen-containing heterocyclic compound and use thereof
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
WO2012080735A1 (en) * 2010-12-16 2012-06-21 Convergence Pharmaceuticals Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US10266526B2 (en) 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
JP2017527577A (en) 2014-09-10 2017-09-21 エピザイム，インコーポレイティド Substituted pyrrolidine compounds
CA2960279A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
AU2015315167A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamide compounds
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds

Also Published As

Publication number Publication date
KR20170047397A (en) 2017-05-04
US10577363B2 (en) 2020-03-03
WO2016040515A1 (en) 2016-03-17
CA2960280A1 (en) 2016-03-17
EP3193605A1 (en) 2017-07-26
CN107072207A (en) 2017-08-18
JP2017528464A (en) 2017-09-28
IL250888A0 (en) 2017-04-30
US20170362217A1 (en) 2017-12-21
BR112017004589A2 (en) 2018-01-23
MX2017002986A (en) 2017-10-24
EA201790327A1 (en) 2017-10-31
SG11201701597RA (en) 2017-03-30
EP3193605A4 (en) 2018-04-18
AU2015315182A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
SG10201901192TA (en) Smyd inhibitors
SG10201901189SA (en) Substituted piperidine compounds
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
MX2018012379A (en) Bet protein degraders.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2018013433A (en) Piperidines as menin inhibitors.
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MD4800B1 (en) Aminopyrimidinyl compounds as JAK inhibitors
MX2020001757A (en) Compounds, salts thereof and methods for treatment of diseases.
MA40170A (en) Heterocyclic morphinan derivatives and use thereof
MX2018004664A (en) Ep4 antagonists.
MX2016005760A (en) Gsk-3 inhibitors.
MD20170011A2 (en) Imidazopyridazine compounds
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
IN2013MU03862A (en)
EA201700356A1 (en) NEW CYCLOPROPANBENZOFURANILPYRIDOPYRAZINDIONS
MD20160111A2 (en) Cycloalkyl-linked diheterocycle derivatives
EA201590656A1 (en) AZAINDOLINS
MX2015012600A (en) Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors.
EA201491878A8 (en) SUBSTITUTED XANTHINE DERIVATIVES
MX2013005825A (en) Benzoxazepines as inhibitors of mtor and methods of their use and manufacture.
PH12017501214A1 (en) Cgrp antagonist peptides
MX2015013551A (en) Pharmaceutically acceptable amine salts of pitavastatin.